AnaptysBio在溃疡性结肠炎的主要资产的中期试验中遭遇挫折

2025-11-10 22:56

AnaptysBio (ANAB) on Monday announced a failure in a Phase 2 trial for its lead candidate rosnilimab in ulcerative colitis, an inflammatory bowel disorder affecting the large intestine and rectum.
Citing 12-week data, AnaptysBio (ANAB) said the study did not meet the primary endpoint or key secondary endpoints of clinical response and clinical remission, even though rosnilimab was safe and well-tolerated among trial subjects.
The global trial was designed to evaluate the T cell depleter in moderate-to-severe ulcerative colitis, with its primary endpoint being the mean change from baseline in modified Mayo Score ((mMS)).
Concurrently, the company disclosed that results won’t support further development of rosnilimab in UC, and as a result, it will not advance the trial any further, generating $10M in savings.

More on AnaptysBio